New York, NY, October 18, 2023 (Globe Newswire) -- Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) has named Michael Rossi as President and CEO, effective November 6, 2023. Rossi will also join the company's Board of Directors. Y-mAbs focuses on developing and commercializing antibody-based therapeutic products for cancer treatment.
Read full article here.
Rahway, NJ & Cambridge, MA, November 21, 2023 (Business Wire) -- Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc. declare a definitive agr
Zürich, Switzerland, November 16, 2023 (Business Wire) -- Memo Therapeutics AG (“MTx”), a late-stage biotech firm advancing top-tier therapeutic antibodies, discloses the appointment of Erik van den
Marlborough, MA, November 17, 2023 (PRNewswire) -- Boston Scientific Corporation (NYSE: BSX) announces the completion of its acquisition of Relievant Medsystems Inc., the sole provider of the FDA-cl
